Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 11/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 11/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 10/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310021 | 0.94 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL29566401 | 0.94 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL26811442 | 0.92 | NOD2 (0.40) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL29567543 | 0.92 | LCK (0.37) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL24310035 | 0.92 | LCK (0.37) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL26811472 | 0.92 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6TGFBR1 | |
| SCHEMBL29567256 | 0.91 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6 | |
| SCHEMBL24309496 | 0.91 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6 | |
| SCHEMBL24310104 | 0.87 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6GUSB | |
| SCHEMBL29566496 | 0.87 | NOD2 (0.36) | NOD2ACVR1RIPK2HTR6GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NOD2 724/4885ACVR1 1319/4885RIPK2 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.